Siyuan Qian

Dr. Siyuan Qian

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
VDVíctor Domínguez-Prieto
Víctor Domínguez-Prieto
SQSiyuan Qian
Siyuan Qian
PVPedro Villarejo-Campos
Pedro Villarejo-Campos
CMCecilia Meliga
Cecilia Meliga
SGSara González-Soares
Sara González-Soares
DGDamián García-Olmo
Damián García-Olmo
Ovarian cancer is the seventh most common cancer worldwide in women and the most lethal gynecologic malignancy due to the lack of accurate screening tools for early detection and late symptom onset. The absence of early-onset symptoms often delays diagnosis until the disease has progressed to advanced stages, frequently when there is peritoneal involvement. Although ovarian cancer is a heterogeneous malignancy with different histopathologic types, treatment for advanced tumors is usually based on chemotherapy and cytoreduction surgery. CAR T cells have shown promise for the treatment of hematological malignancies, though their role in treating solid tumors remains unclear. Outcomes are less favorable owing to the low capacity of CAR T cells to migrate to the tumor site, the influence of the protective tumor microenvironment, and the heterogeneity of surface antigens on tumor cells. Despite these results, CAR T cells have been proposed as a treatment approach for peritoneal carcinomatosis from colorectal and gastric origin. Local intraperitoneal administration of CAR T cells has been found to be superior to systemic administration, as this route is associated with increased tumor reduction, a more durable effect, protection against local relapse and distant metastases, and fewer systemic adverse effects. In this article we review the application of CAR T cells for the treatment of ovarian cancer and peritoneal carcinomatosis from ovarian cancer.

23 November 2023 in Cytotherapy
Verified
Journal Article
Closed access
SQSiyuan Qian
Siyuan Qian
JCJun Chen
Jun Chen
YZYongchun Zhao
Yongchun Zhao
XZXiuxiu Zhu
Xiuxiu Zhu
DDDepeng Dai
Depeng Dai
CQCheng Qian
Cheng Qian

27 February 2026 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
YGYang Gao
Yang Gao
JLJie Li
Jie Li
HZHangyu Zhang
Hangyu Zhang
YZYingzi Zhang
Yingzi Zhang
SQSiyuan Qian
Siyuan Qian
WFWeijia Fang
Weijia Fang

25 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
SQSiyuan Qian
Siyuan Qian
PVPedro Villarejo-Campos
Pedro Villarejo-Campos
IGIsmael Guijo
Ismael Guijo
SHSergio Hernández-Villafranca
Sergio Hernández-Villafranca
DGDamián García-Olmo
Damián García-Olmo
CQCheng Qian
Cheng Qian
Latest advances in the field of cancer immunotherapy have developed the (Chimeric Antigen Receptor) CAR-T cell therapy. This therapy was first used in hematological malignancies which obtained promising results; therefore, the use of CAR-T cells has become a popular approach for treating non-solid tumors. CAR-T cells consist of T-lymphocytes that are engineered to express an artificial receptor against any surface antigen of our choice giving us the capacity of offering precise and personalized treatment. This leaded to the development of CAR-T cells for treating solid tumors with the hope of obtaining the same result; however, their use in solid tumor and their efficacy have not achieved the expected results. The reason of these results is because solid tumors have some peculiarities that are not present in hematological malignancies. In this review we explain how CAR-T cells are made, their mechanism of action, adverse effect and how solid tumors can evade their action, and also we summarize their use in colorectal cancer and peritoneal carcinomatosis.

Verified
Journal Article
Open access
PDF file
Pedro VILLAREJO Villarejo-camposPedro VILLAREJO Villarejo-campos
Pedro VILLAREJO Villarejo-campos
MGMariano García-Arranz
Mariano García-Arranz
SQSiyuan Qian
Siyuan Qian
SGSantos Jiménez de Los Galanes
Santos Jiménez de Los Galanes
VDVíctor Domínguez-Prieto
Víctor Domínguez-Prieto
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
Pseudomyxoma peritonei (PMP) is a rare malignant growth characterized by the production of mucin and the potential for peritoneal relapse. This study aimed to investigate the immunohistochemical and biological characteristics of mucin in patients with cellular and acellular PMP. We prospectively analyzed mucin specimens obtained from our patient cohort and described the composition and type of mucin present in each sample. A metagenomic analysis of the samples was performed to investigate the bacterial composition of the PMP microbiome. Secreted mucins 2 and 5AC and membrane-associated mucin-1 were the primary components of mucin in both cellular and acellular tumor specimens. The metagenomic study revealed a predominance of the phylum Proteobacteria and the genus Pseudomonas. Notably, Pseudomonas plecoglossicida, a species not previously reported in the human microbiome, was found to be the most abundant organism in the mucin of pseudomyxoma peritonei. Our findings suggest that the presence of MUC-2 and mucin colonization by Pseudomonas are characteristic features of both cellular and acellular disease. These results may have significant implications for the diagnosis and treatment of this rare entity.

28 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SQSiyuan Qian
Siyuan Qian
Pedro VILLAREJO Villarejo-camposPedro VILLAREJO Villarejo-campos
Pedro VILLAREJO Villarejo-campos
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown poor effectiveness in treating peritoneal carcinomatosis (PC) of gastric origin with a high tumor burden (high peritoneal cancer index), though there are scarce therapy alternatives that are able to improve survival. In experimental studies, chimeric antigen receptor-T (CAR-T) cell therapy has shown encouraging results in gastric cancer and is currently being evaluated in several clinical trials. Regarding PC, CAR-T cell therapy has also proven useful in experimental studies, especially when administered intraperitoneally, as this route improves cell distribution and lifespan. Although these results need to be supported by ongoing clinical trials, CAR-T cells are a promising new therapeutic approach to peritoneal metastases from gastric cancer. In this review, we summarize the current evidence of the use of CAR-T cells in gastric cancer and PC of gastric origin.